On 13 January 2026, Celltrion revealed at the 44th Annual J.P. Morgan Healthcare Conference that it plans to commercialise up to 18 biosimilar products by 2030 and 41 products by 2038. This is a slight reduction of its plans announced in September 2024 to have a “portfolio of 22 [biosimilar] products by 2030”.
Celltrion currently has 11 biosimilars approved in various jurisdictions, namely adalimumab, aflibercept, bevacizumab, denosumab, infliximab/SC infliximab, omalizumab, rituximab, tocilizumab, trastuzumab, and ustekinumab.
Celltrion also unveiled at the J.P. Morgan Healthcare Conference that it plans to submit up to 16 investigational new drug (IND) applications by 2028, including up to 10 antibody-drug conjugates (ADCs), 4 multi-specific antibodies (msAbs), 1 recombinant protein and 1 peptide. Three Celltrion IND applications for ADCs (CT-P70, CT-P71 and CT-P73) were accepted by the FDA in 2025.
On 6 January 2026, Celltrion officially opened its first US manufacturing facility, which it acquired from Eli Lilly in late 2025. Under the deal, Celltrion will conduct contract manufacturing operations for Eli Lilly valued at 678.7 billion won (US$470.5 million) over a 3-4 year period. According to Celltrion, the acquisition will “ensure long-term supply chain resilience” by eliminating tariff and trade risks and strengthening its competitiveness in the US market.